Diversify Advisory Services LLC Buys Shares of 18,594 Repligen Corporation $RGEN

Diversify Advisory Services LLC acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,594 shares of the biotechnology company’s stock, valued at approximately $2,437,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. M&T Bank Corp bought a new stake in Repligen during the 4th quarter worth approximately $29,819,000. Avidity Partners Management LP boosted its position in shares of Repligen by 54.7% in the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares during the period. Swedbank AB bought a new position in shares of Repligen in the fourth quarter worth approximately $4,146,000. Conestoga Capital Advisors LLC increased its stake in shares of Repligen by 10.6% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after purchasing an additional 101,062 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Repligen during the 4th quarter valued at $20,253,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RGEN. Citigroup raised Repligen to a “buy” rating in a report on Tuesday, July 7th. Barclays increased their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Wells Fargo & Company lifted their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Evercore reissued an “outperform” rating and issued a $160.00 target price on shares of Repligen in a report on Monday, July 6th. Finally, Royal Bank Of Canada initiated coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $166.43.

Repligen Trading Down 1.7%

RGEN opened at $166.15 on Wednesday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average is $144.29 and its two-hundred day moving average is $131.18. The company has a market capitalization of $9.38 billion, a P/E ratio of 227.60, a PEG ratio of 3.04 and a beta of 1.03. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. During the same period in the prior year, the business earned $0.26 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.